Erfan, GamzeCarrera, CristinaMalvehy, JosepPuig, Susana2022-05-112022-05-1120170001-55551651-2057https://hdl.handle.net/20.500.11776/8656[No Abstract Available]eninfo:eu-repo/semantics/closedAccessMetastatic MelanomaMek InhibitorsCombinationVemurafenibToxicitiesTherapyManagementCutaneous Side Effects of Single Versus Combined BRAF Inhibitors: A Comment to Erfan et al. ReplyEditorial971012671268Q1WOS:000419735400028